Please login to the form below
vitiligo
This page shows the latest vitiligo news and features for those working in and with pharma, biotech and healthcare.
FDA approves Incyte’s Opzelura for vitiligo
It is the first and only FDA-approved product for repigmentation in patients with nonsegmental vitiligo. ... With this latest approval, Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo.
Latest news
-
Almirall launches call on AlmirallShare to find innovative therapies for skin diseases
The assets may have the potential to target immuno-inflammatory pathways for dermatological indications like atopic dermatitis, hidradenitis suppurativa, alopecia areata or vitiligo.
-
Almirall and Inserm Transfert to develop innovative vitiligo treatments
Vitiligo remains a neglected market with a high unmet medical need for treatments, particularly for patients’ hands. ... Karl Ziegelbauer, chief scientific officer at Almirall, said: “Vitiligo can have a huge impact on patients' quality of life.
-
Malcolm's Market Eye: 1 to 7 December
York gets a substantial revenue from Zindaclin for the treatment of acne and Vitix for vitiligo: both products contribute total revenue of GBP 5m, as a result of its recent purchase
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
